No Data
Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Allogene Therapeutics To Present Pre-Clinical Data Highlighting Potential Of ALLO-329 At ACR Convergence
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
Allogene Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target